Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Benchmark Holdings shares jump 29% after it puts up the for sale sign

Shares in Benchmark Holdings PLC rose 29% after the aquaculture genetics specialist announced a strategic review and formal sale process.

This decision, influenced by the board's belief that the current share price significantly undervalues Benchmark's businesses and prospects, follows three years of substantial revenue growth, improved profitability, and cash conversion.

In that time, Benchmark's revenue increased from £105.4m to £169.5m, and Adjusted EBITDA grew from £15.5m to £35.5m.

The review will explore options including selling the company wholly or in parts.

Benchmark stock rose 10p to 45p on the news.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK